Company: ARWR
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001628280-25-038858
Chunk: 13

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 13
---
ITEM 1.    FINANCIAL STATEMENTS 

Arrowhead Pharmaceuticals, Inc.

Consolidated Balance Sheets 

(in thousands, except per share amounts)

June 30, 2025September 30, 2024(unaudited)ASSETSCurrent assets:Cash, cash equivalents and restricted cash$129,793 $102,685 Accounts receivable9,699 — Available-for-sale securities, at fair value770,579 578,276 Prepaid expenses23,692 9,537 Other current assets13,160 4,973 Total current assets946,923 695,471 Property, plant and equipment, net381,048 386,032 Intangible assets, net7,286 8,562 Right-of-use assets44,002 45,255 Other assets1,353 4,482 Total Assets$1,380,612 $1,139,802 LIABILITIES, NONCONTROLLING INTEREST AND STOCKHOLDERS’ EQUITYCurrent liabilities:Accounts payable$33,050 $11,388 Accrued expenses64,818 63,017 Accrued payroll and benefits19,298 21,989 Lease liabilities7,010 6,342 Deferred revenue22,979 — Credit facility40,000 — Other liabilities7,375 432 Total current liabilities194,530 103,168 Long-term liabilities:Lease liabilities, net of current portion105,690 111,027 Liability related to the sale of future royalties360,254 341,361 Credit facility, net of current portion200,332 393,183 Total long-term liabilities666,276 845,571 Commitments and contingencies (Note 7)Noncontrolling interest and stockholders’ equity:Common stock, $0.001 par value:Authorized 290,000 shares; issued and outstanding 138,144 and 124,376 shares230 217 Additional paid-in capital2,120,130 1,806,000 Accumulated other comprehensive income5,357 4,750 Accumulated deficit(1,603,404)(1,625,523)Stockholders’ equity522,313 185,444 Noncontrolling interest(2,507)5,619 Total noncontrolling interest and stockholders’ equity519,806 191,063 Total